, Depression: A Global Crisis, WHO, 2012.

G. Fond, C. Lancon, P. Auquier, and L. Boyer, Prevalence of major depression in France in the general population and in specific populations from, Presse Med. Paris Fr, vol.48, pp.365-375, 1983.

G. Fond, M. Masson, P. Auquier, D. Da-fonseca, C. Lançon et al., The key role of psychiatry in the development of French health-related sustainable development goals, L'Encephale, vol.45, pp.99-100, 2019.

P. Sobocki, B. Jönsson, J. Angst, and C. Rehnberg, Cost of depression in Europe, J. Ment. Health Policy Econ, vol.9, pp.87-98, 2006.

P. E. Greenberg, A. Fournier, T. Sisitsky, C. T. Pike, and R. C. Kessler, The economic burden of adults with major depressive disorder in the United States, J. Clin. Psychiatry, vol.76, pp.155-162, 2005.

G. Fond, M. Masson, C. Lançon, P. Auquier, and L. Boyer, Updating of the French recommendations for the first-line treatment of major depression, L'Encephale, vol.45, pp.457-458, 2019.

S. I. Hay, A. A. Abajobir, K. H. Abate, C. Abbafati, K. M. Abbas et al., DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016, Lancet Lond. Engl, vol.390, pp.1260-1344, 2016.

M. Andrianarisoa, L. Boyer, O. Godin, L. Brunel, E. Bulzacka et al., Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort, Schizophr. Res, vol.185, pp.173-181, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01792072

G. Fond, L. Boyer, F. Berna, O. Godin, E. Bulzacka et al., Remission of depression in patients with schizophrenia and comorbid major depressive disorder: Results from the FACE-SZ cohort, Br. J. Psychiatry, vol.213, pp.464-470, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01814845

M. Alessandrini, C. Lançon, G. Fond, C. Faget-agius, R. Richieri et al., A structural equation modelling approach to explore the determinants of quality of life in schizophrenia, Schizophr. Res, vol.171, pp.27-34, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482502

G. Fond, O. Godin, M. Dumontaud, C. Faget, F. Schürhoff et al., Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.94, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02473659

J. Kucerova, Z. Babinska, K. Horska, and H. Kotolova, The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review, Biomed. Pap. Med. Fac. Univ. Palacký Olomouc Czechoslov, vol.159, pp.208-214, 2015.

A. Gregory, P. Mallikarjun, and R. Upthegrove, Treatment of depression in schizophrenia: Systematic review and meta-analysis, Br. J. Psychiatry J. Ment. Sci, vol.211, pp.198-204, 2017.

O. Godin, M. Leboyer, F. Schürhoff, L. Boyer, M. Andrianarisoa et al., Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort, J. Psychiatr. Res, vol.94, pp.62-69, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01696840

G. Fond, L. Boyer, M. Andrianarisoa, O. Godin, E. Bulzacka et al., Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.85, pp.62-68, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01814764

S. Nakajima, H. Takeuchi, G. Fervaha, E. Plitman, J. K. Chung et al., Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data, Schizophr. Res, vol.161, pp.429-433, 2015.

T. Wykes, J. M. Haro, S. R. Belli, C. Obradors-tarragó, C. Arango et al., Mental health research priorities for Europe, Lancet Psychiatry, vol.2, pp.1036-1042, 2015.

A. Cipriani, T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis, Lancet Lond. Engl, vol.391, pp.1357-1366, 2018.

X. Zhu, Y. Han, J. Du, R. Liu, K. Jin et al., Microbiota-gut-brain axis and the central nervous system, Oncotarget, vol.8, pp.53829-53838, 2017.

G. Fond, G. Chevalier, G. Eberl, and M. Leboyer, The potential role of microbiota in major psychiatric disorders: Mechanisms, preclinical data, gastro-intestinal comorbidities and therapeutic options, Presse Med. Paris Fr, vol.45, pp.7-19, 1983.

A. C. Campos, N. P. Rocha, J. R. Nicoli, L. Q. Vieira, M. M. Teixeira et al., Absence of gut microbiota influences lipopolysaccharide-induced behavioral changes in mice, Behav. Brain Res, vol.312, pp.186-194, 2016.

E. G. Severance, E. Prandovszky, J. Castiglione, and R. H. Yolken, Gastroenterology issues in schizophrenia: Why the gut matters, Curr. Psychiatry Rep, vol.17, 2015.

E. G. Severance, K. L. Gressitt, C. R. Stallings, A. E. Origoni, S. Khushalani et al., Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia, Schizophr. Res, vol.148, pp.130-137, 2013.

G. Fond, C. Lançon, P. Auquier, and L. Boyer, C-reactive protein as a peripheral biomarker in schizophrenia. An updated systematic review, Front. Psychiatry, vol.9, p.392, 2018.

L. M. Rowland, H. K. Demyanovich, S. A. Wijtenburg, W. W. Eaton, K. Rodriguez et al., Antigliadin antibodies (AGA IgG) are related to neurochemistry in schizophrenia, vol.8, 2017.

G. A. Rook, C. L. Raison, C. A. Lowry, and . Microbiota, immunoregulatory old friends and psychiatric disorders, Adv. Exp. Med. Biol, vol.817, pp.319-356, 2014.

D. Rodrigues-amorim, T. Rivera-baltanás, B. Regueiro, C. Spuch, M. E. De-las-heras et al., The role of the gut microbiota in schizophrenia: Current and future perspectives, World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry, vol.19, pp.571-585, 2018.

E. Schwarz, J. Maukonen, T. Hyytiäinen, T. Kieseppä, M. Ore?i? et al., Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response, Schizophr. Res, vol.192, pp.398-403, 2018.

Y. Shen, J. Xu, Z. Li, Y. Huang, Y. Yuan et al., Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study, Schizophr. Res, vol.197, pp.470-477, 2018.

O. Godin, M. Leboyer, A. Gaman, B. Aouizerate, F. Berna et al., Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort, Schizophr. Res, vol.168, pp.388-394, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01755227

G. Fond, O. Godin, L. Boyer, F. Berna, M. Andrianarisoa et al., Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort, Eur. Arch. Psychiatry Clin. Neurosci, vol.269, pp.985-992, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02473643

G. Fond, N. Resseguier, F. Schürhoff, O. Godin, M. Andrianarisoa et al., Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: Results from the national FACE-SZ cohort, Eur. Arch. Psychiatry Clin. Neurosci, vol.268, pp.541-553, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01696697

G. Fond, F. Berna, M. Andrianarisoa, O. Godin, M. Leboyer et al., Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: Results from the national multicentric FACE-SZ cohort, Eur. Arch. Psychiatry Clin. Neurosci, vol.267, pp.465-472, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01779626

G. Fond, O. Godin, L. Brunel, B. Aouizerate, F. Berna et al., Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set, J. Affect. Disord, vol.191, pp.209-215, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482510

M. Faugere, J. Micoulaud-franchi, C. Faget-agius, C. Lançon, M. Cermolacce et al., High C-reactive protein levels are associated with depressive symptoms in schizophrenia, J. Affect. Disord, vol.225, pp.671-675, 2018.

D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, Br. Med. J, vol.339, 2009.

G. Fond, A. Loundou, N. Hamdani, W. Boukouaci, A. Dargel et al., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci, vol.264, pp.651-660, 2014.

J. Peter, C. Fournier, M. Durdevic, L. Knoblich, B. Keip et al., A Microbial signature of psychological distress in irritable bowel syndrome, Psychosom. Med, vol.80, pp.698-709, 2018.

J. R. Kelly, Y. Borre, C. O'-brien, E. Patterson, S. El-aidy et al., Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat, J. Psychiatr. Res, vol.82, pp.109-118, 2016.

A. Naseribafrouei, K. Hestad, E. Avershina, M. Sekelja, A. Linløkken et al., Correlation between the human fecal microbiota and depression, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, vol.26, pp.1155-1162, 2014.

S. C. Kleiman, H. J. Watson, E. C. Bulik-sullivan, E. Y. Huh, L. M. Tarantino et al., The intestinal microbiota in acute anorexia nervosa and during renourishment: Relationship to depression, anxiety, and eating disorder psychopathology, Psychosom. Med, vol.77, pp.969-981, 2015.

Y. Liu, L. Zhang, X. Wang, Z. Wang, J. Zhang et al., Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, vol.14, pp.1602-1611, 2016.

H. Jiang, Z. Ling, Y. Zhang, H. Mao, Z. Ma et al., Altered fecal microbiota composition in patients with major depressive disorder, Brain. Behav. Immun, vol.48, pp.186-194, 2015.

J. Chen, P. Zheng, Y. Liu, X. Zhong, H. Wang et al., Sex differences in gut microbiota in patients with major depressive disorder, Neuropsychiatr. Dis. Treat, vol.14, pp.647-655, 2018.

Z. Chen, J. Li, S. Gui, C. Zhou, J. Chen et al., Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder, Neuroreport, vol.29, pp.417-425, 2018.

B. L. Mason, Q. Li, A. Minhajuddin, A. H. Czysz, L. A. Coughlin et al., Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia, J. Affect. Disord, vol.266, pp.394-401, 2020.

A. Madan, D. Thompson, J. C. Fowler, N. J. Ajami, R. Salas et al., The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness, J. Affect. Disord, vol.2020, pp.98-106

P. Lin, B. Ding, C. Feng, S. Yin, T. Zhang et al., Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder, J. Affect. Disord, vol.207, pp.300-304, 2017.

Q. X. Ng, A. Y. Soh, N. Venkatanarayanan, C. Y. Ho, D. Y. Lim et al., A systematic review of the effect of probiotic supplementation on schizophrenia symptoms, Neuropsychobiology, vol.78, pp.1-6, 2019.

J. K. Kiecolt-glaser, S. J. Wilson, M. L. Bailey, R. Andridge, J. Peng et al., Marital distress, depression, and a leaky gut: Translocation of bacterial endotoxin as a pathway to inflammation, Psychoneuroendocrinology, vol.98, pp.52-60, 2018.

R. T. Liu, R. F. Walsh, and A. E. Sheehan, Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials, Neurosci. Biobehav. Rev, vol.102, pp.13-23, 2019.

J. Lagier and D. Raoult, Fecal microbiota transplantation: Indications and perspectives, vol.32, pp.991-997, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01453285

J. Lagier, M. Million, and D. Raoult, Bouillabaisse or fish soup: The Limitations of meta-analysis confronted to the inconsistency of fecal microbiota transplantation studies, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02507368

P. K. Kump, R. Krause, F. Allerberger, and C. Högenauer, Faecal microbiota transplantation-the Austrian approach, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis, vol.20, pp.1106-1111, 2014.

B. Cui, Q. Feng, H. Wang, M. Wang, Z. Peng et al., Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: Safety, feasibility, and efficacy trial results, J. Gastroenterol. Hepatol, vol.30, pp.51-58, 2015.

M. Hocquart, J. Lagier, N. Cassir, N. Saidani, C. Eldin et al., Early fecal microbiota transplantation improves survival in severe clostridium difficile infections, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.66, pp.645-650, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01780637

E. Van-nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal et al., Duodenal infusion of donor feces for recurrent Clostridium difficile, N. Engl. J. Med, vol.368, pp.407-415, 2013.

M. Austin, M. Mellow, and W. M. Tierney, Fecal microbiota transplantation in the treatment of Clostridium difficile infections, Am. J. Med, vol.127, pp.479-483, 2014.

G. Cammarota, L. Masucci, G. Ianiro, S. Bibbò, G. Dinoi et al., Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection, Aliment. Pharmacol. Ther, vol.41, pp.835-843, 2015.

Y. Li, H. Cai, Z. Wang, J. Xu, and J. Fang, Systematic review with meta-analysis: Long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection, Aliment. Pharmacol. Ther, vol.43, pp.445-457, 2016.

S. Paramsothy, M. A. Kamm, N. O. Kaakoush, A. J. Walsh, J. Van-den-bogaerde et al., Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial, Lancet, vol.389, pp.1218-1228, 2017.

S. P. Costello, P. A. Hughes, O. Waters, R. V. Bryant, A. D. Vincent et al., Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial, JAMA, vol.321, pp.156-164, 2019.

P. H. Johnsen, F. Hilpüsch, J. P. Cavanagh, I. S. Leikanger, C. Kolstad et al., Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial, Lancet Gastroenterol. Hepatol, vol.3, pp.17-24, 2018.

S. Wang, M. Xu, W. Wang, X. Cao, M. Piao et al., Systematic review: Adverse events of fecal microbiota transplantation, PLoS ONE, vol.11, 2016.

H. J. Flint, Obesity and the gut microbiota, J. Clin. Gastroenterol, vol.45, pp.128-132, 2011.

K. Rao, V. B. Young, and P. N. Malani, Capsules for fecal microbiota transplantation in recurrent clostridium difficile Infection: The new way forward or a tough pill to swallow?, JAMA, vol.318, 1979.

D. Kao, B. Roach, M. Silva, P. Beck, K. Rioux et al., Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: A randomized clinical trial, JAMA, vol.318, 1985.

C. Staley, M. J. Hamilton, B. P. Vaughn, C. T. Graiziger, K. M. Newman et al., Successful resolution of recurrent clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study, Am. J. Gastroenterol, vol.112, pp.940-947, 2017.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI